An increasing body of experimental evidence (1) supports the concept that subsets of T lymphocytes that suppress humoral and cell-mediated immune responses participate in a defined pathway that is governed by complimentary receptor-antireceptor interactions. Cells at various stages of this pathway can be distinguished by surface phenotype, specificity, and functional effects. The earliest evidence supporting this notion came from the studies of Eardley et al. (2), who showed that Lyt-1 +2-cells act on Lyt-l+2 + precursors and trigger them to mature into potent suppressor T cells (Ts). More recent experiments analyzing suppression of delayed hypersensitivity responses to the haptens, azobenzenearsonate (ABA), and nitrophenyl, indicate that antigen-reactive Ts (termed Tsl) induce second-order anti-idiotypic Ts2, which suppress the hapten-specific immune response, probably by inducing or functioning in concert with a third, antigen-specific cell termed Ts3 (3, 4).
reasoned that these cells corresponded to Tsa and needed to differentiate further in vitro to develop into effector Ts (3, 4) . We report our attempts to generate effector Ts using a protocol that was first established in studies of the suppression of ABA-specific immunity. In principle, this protocol involves immunization of mice with a soluble extract of Tsa cells and subcutaneous priming with antigen-(or, in the present system, M315 IgA-) modified splenoeytes (3). Our results indicate that it is possible to generate effector Ts reactive with myeloma idiotypes and that such Ts differ from Tsl in the kinetics of their effect and in surface phenotype.
Materials and Methods
Induction of Suppressor T Cells. BALB/c mice (12-16 wk of age, purchased from Cumberland Farms, Clinton, TN) were injected intravenously with 5-10 × 107 viable syngeneie splenocytes to which affinity-purified M315 IgA was coupled, using the covalent coupling reagent 1-ethyl 3-(3-diaminopropyl) carhodiimide, as described previously (5) . Spleen cells were removed 6 or 7 d later and were depleted of erythrocytes by treatment with Tris-buffered 0.83% NH4CI. B lymphocytes were removed by binding to dishes coated with affinity-purified rabbit anti-mouse Ig (9); such preparations routinely contained <2% surface Ig-bearing cells by immunofluorescence and showed a >90% depletion of lipopolysaccharide responsiveness. These cells are referred to as Tsl. Soluble extracts of Tsl cells (TsF1) were prepared by four cycles of freezing and thawing and centrifugation at 12,000 g for removing cellular debris. To induce effector Ts, BALB/c mice were immunized subcutaneously with 3 × 107 viable M315 IgA-coupled syngeneic ....... 7
splenocytes at two sites on the flank and were g~ven dally intravenous rejections of 2 × 10 cell equivalents of TsF1 for the next 5 d. Spleen cells were removed 1 d later, and T lymphocytes were prepared as for Tsl. Myeloma Cell Cultures and Assays. These techniques have been described previously (15) Briefly, tissue culture-adapted MOPC 315 cells were centrifuged over Ficoll-Isopaque, and ,v viable myeloma cells were cultured with varying numbers of T lymphocytes in flat-bottomed 96-well Linbro wells (Flow Laboratories, McLean, VA) in triplicate. Cultures were done in 0.2 ml of RPMI 1640 supplemented with 2 mM L-glutamine, penicillin, streptomycin, nonessential amino acids, 5 × 10-M 2-mercaptoethanol, and 10% heat-inactivated fetal calf serum (all from Gibco Laboratories, Grand Island Biological Co., Grand Island, NY) in a humidified atmosphere of 5% CO2. At the end of culture, the cells were harvested, washed once, and aliquots were used to (a) measure viable myeloma cell recovery, viability being assessed by trypan blue dye exclusion, and (b) determine the numbers of IgA-seereting cells by a reverse hemolytic plaque assay using Staphylococcus protein A-coated sheep erythrocytes as indicator cells (5) . Results are expressed as IgA plaque-forming cells (PFC) per 103 viable myeloma cells recovered, and statistical analyses were done by Student's t tests.
Other Techniques. For depletion of various T cell subsets, aliquots of cells were treated with monoclonal anti-Thy-1.2, anti-Lyt-1.2, or anti-Lyt-2.2 antibody (New England Nuclear, Boston, MA) in serum-free L-15 for 40 min at room temperature. After one wash, the cells were treated with 1:8-1:10 dilution of low-tox rabbit complement (Cedarlane Laboratories, Hornby, Ontario, Canada) in L-15 for 45 min at 37°C, and viable cell recovery was determined after three washes. Dish binding experiments were done as previously described (5, 6), using plastic dishes coated with various myeloma Ig to deplete T cells of appropriate specificities.
Results and Discussion
Previous experiments had established that M315-specific Tsx, induced by intravenous immunization with M315-coupled spleen cells, suppressed IgA secretion by the MOPC 315 myeloma after 3-4 d of co-culture (5). In the first series of experiments, we compared ttie kinetics of suppression induced by culturing MOPC 315 cells with TSl and T cells generated by subcutaneous immunization with M315-coupled splenocytes, together with administration of TsFa. The pooled data illustrated in Fig. 1 show that Tsa produce significant inhibition of IgA PFC after >2 d culture with , it can be predicted that M315-specific TsFI induces a second-order Ts2 whose specificity is anti-(anti-M315), and subcutaneous immunization with M315-coupled cells leads to the generation of the effector Ts (Ts3). However, we have not yet been able to demonstrate the existence of Ts2 in the MOPC 315 system because of the lack of a definitive marker for specificity. Moreover, it has not been possible to generate effector Ts by in vitro culture of Tsl, as has been done for nitrophenylreactive Ts (4). The specificity of the effector Ts was assessed by their ability to bind to different myeloma proteins. As shown in Table I , suppressive activity can be depleted by absorbing effector Ts on dishes coated with M315 IgA but not on dishes coated with MPCll (IgG2b,k of unknown specificity) or M460 proteins. MOPC 460 secretes an IgA, k antibody that has the same specificity for dinitrophenyl and trinitrophenyl as MOPC 315 but has largely dissimilar idiotypic determinants (10) . Furthermore, M315-specific effector Ts do not inhibit MPC 11 cells and cause >70% selective suppression of IgA secretion by the MOPC 315-MPCll somatic cell hybrid. This selective effect is observed with hemolytic plaque assays as well as gel electrophoretic analysis ofimmunoprecipitated Ig produced by the somatic cell hybrid (G. Moser, M. Takoaki, I. Fox, M. I. Greene, and A. K. Abbas, manuscript in preparation).
Finally, antibody and complement treatment of suppressor cells showed that the effector Ts are Thy-l.2 +, Lyt-1-2 + cells (Table II) . In contrast, the suppressive effect of Tsl can be abrogated by treating the cells with either anti-Lyt-1 plus complement or anti-Lyt-2 plus complement, indicating that these cells are either Lyt-l+2 + or that T lymphocytes bearing both Lyt-1 ÷ and Lyt-2 + markers are necessary for Tsa to induce or mature into effector Ts in vitro (2) . Alternatively, Tsx may initiate the sequence of complimentary receptor-antireceptor interactions that culminates in the generation of effector Ts (1). Studies of the suppression of physiologic immune responses have led to the suggestion that TSl inhibit the inductive or afferent phase of the response because they only mediate suppression when administered at or before the time of immunization (11) . However, our observations that Tsx manifest a delayed effect, even on myelorna targets that are obviously independent of inductive signals, suggests that the apparent "afferent suppression" of normal immune responses mediated by Tsl might be the result of expansion or maturation of these cells or induction of effector Ts, which occurs concomitant with the development of the immune response. Such a concept, which implies that Tsa generated with antigen-modified cells in vivo mediate suppression not by themselves but by developing into or inducing effector Ts, is receiving increasing support from several lines of experimental data (reviewed in ref. 1). The ability to induce two cell types at different stages of a suppressor pathway, and to measure their effects on a monoclonal, autonomous target, should facilitate analysis of the differentiation and mechanisms of action of suppressor T lymphocytes. Summary BALB/c mice immunized intravenously with syngeneic splenocytes, to which affinity-purified IgA produced by the MOPC 315 myeloma is covalently coupled, develop suppressor T cells (Tsl) that inhibit IgA secretion by MOPC 315 cells after 3-4 d of co-culture. Immunization with M315-coupled splenocytes subcutaneously, followed by administration of a soluble extract of Tsl cells, leads to the generation of effector Ts that are also idiotype specific and inhibit myeloma function within 1 d. Moreover, effector Ts are Lyt-1-2 ÷, whereas Tsl are either Lyt-1 +2 + or require Lyt-1 + and Lyt-2 ÷ cells to mature into effector Ts in vitro. Such a protocol should be useful for analyzing the interactions that result in the maturation of Ts and in defining the mechanisms of action of Ts, whose effect can be measured on a homogeneous target population and that are specific for a well-characterized myeloma idiotype.
